500-76-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Hydroxyphenoxy)benzoic acid is used as an active pharmaceutical ingredient for the development of drugs. Its unique chemical structure allows it to be a key component in the formulation of medications targeting a range of health conditions.
Used in Dye and Pigment Synthesis:
In the chemical industry, 4-(4-Hydroxyphenoxy)benzoic acid is utilized as a precursor in the synthesis of dyes and pigments. Its chemical properties contribute to the color and stability of these products, making it an essential component in their production.
Used as a Chemical Intermediate:
4-(4-Hydroxyphenoxy)benzoic acid serves as a chemical intermediate in the manufacture of various organic compounds. Its role in the synthesis process is crucial for creating a wide array of end products used in different sectors, including but not limited to pharmaceuticals, materials science, and specialty chemicals.
Used in Research and Development:
Due to its potential applications and chemical versatility, 4-(4-Hydroxyphenoxy)benzoic acid is also used in research and development settings. Scientists and researchers leverage its properties to explore new chemical reactions, syntheses, and potential applications, further expanding its utility in the scientific community.

InChI:InChI=1/C13H10O4/c14-10-3-7-12(8-4-10)17-11-5-1-9(2-6-11)13(15)16/h1-8,14H,(H,15,16)

Upstream product

• 3525-22-2 4'-(4-methoxyphenoxy)benzoic acid 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 78725-47-0 4-(4-methoxyphenoxy)benzaldehyde 
• 150-76-5 4-methoxy-phenol 
• 459-57-4 4-fluorobenzaldehyde 
• 620632-58-8 benzyl 4-(4-benzyloxyphenoxy)benzoate 

Downstream Products

• 39177-38-3 4-(4-acetoxy-phenoxy)-benzoic acid 
• 262447-07-4 N-(4-{[Amino(2-thienyl)methylidene]amino}phenethyl)-4-(4-hydroxyphenoxy)benzamide Hydrochloride 
• 131802-89-6 methyl 4-(4-hydroxyphenoxy)benzoate 
• 1562024-19-4 N-(19-((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)-4,7,10,13,16-pentaoxanonadecyl)-4-(4-hydroxyphenoxy)benzamide 
• 1257087-18-5 cyanomethyl (11β,17α)-17-{[4-(4-acetoxyphenoxy)benzoyl]oxy}-9-fluoro-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate 
• 1436378-63-0 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(4-hydroxyphenoxy)benzamide 

Relevant academic research and scientific papers

Selective cleavage of aryl methyl ether moiety of aryloxy aryl methyl ether by 48% HBr/tetra-n-butylphosphonium bromide

Aryl methyl ether moiety in the molecule containing aryl aryl ether part along with aryl methyl ether part is selectively cleaved to give the desired substituted phenol in excellent yield by using 48% HBr in the presence of tetra-n-butylphosphonium bromid

1-substituted 4-arylpiperazine as kappa opioid receptor antagonists

Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2- methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists

There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [35S] GTPγS binding assay showed that neither compound showed the high potency and κ opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [35S]GTPγS binding stimulated by the selective κ opioid agonist U69,593. These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3- methylpiperazin-1-yl]methyl}-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good κ opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [35S]GTPγS binding assay showed that several of the analogues were potent and selective κ opioid receptor antagonists.

1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS

Provided are compounds represented by the formula: where R, Y3, R1,R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors

The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione; metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, W, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.